Investors

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Net assets

£1455m

Fully diluted NAV per share

217p

NAV total return

37.9%

Capital pool available to invest in life science

£400m

New companies formed in 2019

3

Proceeds from the sale of Nightstar

£256m

FY2020 Outlook

  • Sales and earnings growth in Blue Earth
  • Strong progress in our clinical pipeline, including high impact data read outs
  • New company formations and financings; capital deployment of £100-200m